These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25984303)

  • 1. Possible FDA-approved drugs to treat Ebola virus infection.
    Yuan S
    Infect Dis Poverty; 2015; 4():23. PubMed ID: 25984303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.
    Johansen LM; Brannan JM; Delos SE; Shoemaker CJ; Stossel A; Lear C; Hoffstrom BG; Dewald LE; Schornberg KL; Scully C; Lehár J; Hensley LE; White JM; Olinger GG
    Sci Transl Med; 2013 Jun; 5(190):190ra79. PubMed ID: 23785035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Small Molecule Entry Inhibitors of Ebola Virus.
    Basu A; Mills DM; Mitchell D; Ndungo E; Williams JD; Herbert AS; Dye JM; Moir DT; Chandran K; Patterson JL; Rong L; Bowlin TL
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S425-34. PubMed ID: 26206510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles.
    Ndungo E; Herbert AS; Raaben M; Obernosterer G; Biswas R; Miller EH; Wirchnianski AS; Carette JE; Brummelkamp TR; Whelan SP; Dye JM; Chandran K
    mSphere; 2016; 1(2):. PubMed ID: 27303731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.
    Kouznetsova J; Sun W; Martínez-Romero C; Tawa G; Shinn P; Chen CZ; Schimmer A; Sanderson P; McKew JC; Zheng W; García-Sastre A
    Emerg Microbes Infect; 2014 Dec; 3(12):e84. PubMed ID: 26038505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.
    Brannan JM; Froude JW; Prugar LI; Bakken RR; Zak SE; Daye SP; Wilhelmsen CE; Dye JM
    J Infect Dis; 2015 Oct; 212 Suppl 2():S282-94. PubMed ID: 25943199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells.
    Geisbert TW; Young HA; Jahrling PB; Davis KJ; Larsen T; Kagan E; Hensley LE
    Am J Pathol; 2003 Dec; 163(6):2371-82. PubMed ID: 14633609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
    Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
    J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein.
    Yi D; Li Q; Wang H; Lv K; Ma L; Wang Y; Wang J; Zhang Y; Liu M; Li X; Qi J; Shi Y; Gao GF; Cen S
    Acta Pharm Sin B; 2022 Dec; 12(12):4378-4389. PubMed ID: 36561997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
    Warfield KL; Swenson DL; Olinger GG; Kalina WV; Aman MJ; Bavari S
    J Infect Dis; 2007 Nov; 196 Suppl 2():S430-7. PubMed ID: 17940980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALIX Rescues Budding of a Double PTAP/PPEY L-Domain Deletion Mutant of Ebola VP40: A Role for ALIX in Ebola Virus Egress.
    Han Z; Madara JJ; Liu Y; Liu W; Ruthel G; Freedman BD; Harty RN
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S138-45. PubMed ID: 25786915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Ebola Virus Infection: Identification of Niemann-Pick C1 as the Target by Optimization of a Chemical Probe.
    Lee K; Ren T; Côté M; Gholamreza B; Misasi J; Bruchez A; Cunningham J
    ACS Med Chem Lett; 2013 Feb; 4(2):239-243. PubMed ID: 23526644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens.
    Sisk JM; Frieman MB
    ACS Infect Dis; 2015 Sep; 1(9):401-2. PubMed ID: 27617922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo.
    Finch CL; Dyall J; Xu S; Nelson EA; Postnikova E; Liang JY; Zhou H; DeWald LE; Thomas CJ; Wang A; Xu X; Hughes E; Morris PJ; Mirsalis JC; Nguyen LH; Arolfo MP; Koci B; Holbrook MR; Hensley LE; Jahrling PB; Schmaljohn C; Johansen LM; Olinger GG; Schiffer JT; White JM
    Microorganisms; 2021 Mar; 9(3):. PubMed ID: 33801811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of Ebola Virus.
    Kuroda M; Fujikura D; Nanbo A; Marzi A; Noyori O; Kajihara M; Maruyama J; Matsuno K; Miyamoto H; Yoshida R; Feldmann H; Takada A
    J Virol; 2015 Jun; 89(12):6481-93. PubMed ID: 25855742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection In Vitro.
    Sadewasser A; Dietzel E; Michel S; Klüver M; Helfer M; Thelemann T; Klar R; Eickmann M; Becker S; Jaschinski F
    Mol Ther Nucleic Acids; 2019 Jun; 16():686-697. PubMed ID: 31125846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection.
    Okumura A; Rasmussen AL; Halfmann P; Feldmann F; Yoshimura A; Feldmann H; Kawaoka Y; Harty RN; Katze MG
    J Virol; 2015 Oct; 89(20):10399-406. PubMed ID: 26246577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination and Therapeutic Exploitation of Ebola Virus Spontaneous Mutation Frequency.
    Alfson KJ; Worwa G; Carrion R; Griffiths A
    J Virol; 2015 Dec; 90(5):2345-55. PubMed ID: 26676781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.